Clodronate: A review of its use in the prevention of bone metastases and the management of skeletal complications associated with bone metastases in patients with breast cancer

Drugs and Aging

Volumn 21, Issue 14, 2004, Pages 949-962

  Dando, Toni M ^a   Wiseman, Lynda R ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID; PLACEBO;

ADVANCED CANCER; BONE METASTASIS; BONE PAIN; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPEPSIA; EMBASE; FOOD DRUG INTERACTION; FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPOPHOSPHATEMIA; MEDLINE; META ANALYSIS; MULTICENTER STUDY; NAUSEA; PHARMACODYNAMICS; PHARMACOECONOMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; VISCERAL METASTASIS; VOMITING;

BONE NEOPLASMS; BREAST NEOPLASMS; CLODRONIC ACID; DISEASE MANAGEMENT; HUMANS;

EID: 10444226607     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421140-00005     Document Type: Review

References (67)

1. Untch M. Importance of bone health in breast cancer. Cancer Today. In press
2. American Cancer Society. Cancer facts and figures 2004 [online]. Available from URL: http://www.cancer.org/downloads/ STT/CAFF_finalPWSecured.pdf [Accessed 2004 Apr 21]
3. Lipton A. Bisphosphonates and metastatic breast carcinoma. Cancer 2003 Feb 1; 97 (3 Suppl.): 848-53
4. Paterson AHG, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65
5. McCloskey EV, Guest JF, Kanis JA. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs 2001; 61 (9): 1253-74
6. Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003 Feb 1; 97 (3 Suppl.): 834-9
7. Mundy G. Realising the potential of anti-host therapy. Cancer Today. In press
8. Hurst M, Noble S. Clodronate: a review of its use in breast cancer. Drugs Aging 1999 Aug; 15 (2): 143-67
9. Green JR. Antitumor effects of bisphosphonates. Cancer 2003 Feb 1; 97 (3 Suppl.): 840-7
10. Santini D, Gentilucci UV, Vincenzi B, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003; 14 (10): 1468-76
11. Van Beek ER, Lowik CW, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 2002 Jan; 30 (1): 64-70
12. Heikkila P, Teronen O, Moilanen M, et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 2002 Mar; 13 (3): 245-54
13. Valleala H, Hanemaaijer R, Mandelin J, et al. Regulation of MMP-9 (gelatinase B) in activated human monocyte/macrophages by two different types of bisphosphonates. Life Sci 2003 Sep 26; 73 (19): 2413-20
14. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000 Jun 1; 60 (11): 2949-54
15. Boissier S, Magnetto S, Frappait L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57: 3890-4
16. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000 Nov; 15 (11): 2211-21
17. Merrell M, Suarez-Cuervo C, Harris KW, et al. Bisphosphonate induced growth inhibition of breast cancer cells is augmented by p38 inhibition. Breast Cancer Res & Treat 2003; 81 (3): 231-41
18. Senaratne SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000 Apr; 82 (8): 1459-68
19. Sonnemann J, Eckervogt V, Truckenbrod B, et al. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001 Jun; 12 (5): 459-65
20. Fassnacht M, Franke A, Dettling A, et al. Clodronate inhibits adrenocortical cell proliferation and P450c21 activity. J Endocrinol 2002 Sep; 174 (3): 509-16
21. Suri S, Monkkonen J, Taskinen M, et al. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 2001 Oct; 29 (4): 336-43
22. Reszka AA, Halasy-Nagy JM, Masarachia PJ, et al. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis: a link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999 Dec 3; 274 (49): 34967-73
23. Fromigue O, Body JJ. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 2002 Jun; 25 (6): 539-46
24. Villikka K, Perttunen K, Rosnell J, et al. The absolute bioavailability of clodronate from two different oral doses. Bone 2002 Sep; 31 (3): 418-21
25. Schering. Bonefos (disodium clodronate): summary of product characteristics (Europe) [online]. Available from URL: http:// www.bonefos.com/pdf/Standard_spc_txt.pdf [Accessed 2004 May 1]
26. Ylitalo P, Holli K, Monkkonen J, et al. Comparison of pharmacokinetics of clodronate after single and repeated doses. Int J Clin Pharmacol Ther 1999 Jun; 37 (6): 294-300
27. Pentikainen PJ, Elomaa I, Nurrni A-K, et al. Pharmacokinetics of clodronate in patients with metastatic breast cancer. Int J Clin Pharmacol Ther Toxicol 1989; 27: 222-8
28. Yakatan GJ, Poynor WJ, Talbert RL, et al. Clodronate kinetics and bioavailability. Clin Pharmacol Ther 1982; 31 (3): 402-10
29. Laitinen K, Patronen A, Harju P, et al. Timing of food intake has a marked effect on the bioavailability of clodronate. Bone 2000 Aug; 27 (2): 293-6
30. Powles T, McCloskey E, Kurkilahti M, et al. Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial [abstract no. 528 plus poster]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans
31. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002 Aug 1; 20 (15): 3219-24
32. Saarto T, Blomqvist C, Virkkunen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients 5-year results of a randomized controlled trial. J Clin Oncol 2001 Jan 1; 19 (1): 10-7
33. Diel IJ, Solomayer E-F, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-63.
34. Kristensen B, Ejlertsen B, Groenvold M, et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999 Jul; 246 (1): 67-74
35. Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases [in French]. Bull Cancer 2001 Jul; 88 (7): 701-7
36. Kanis JA, Powles T, Paterson AHG, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996; 19: 663-7
37. Diel IJ, Solomayer E, Gollan C, et al. Bisphosphonates in the reduction of metastases in breast cancer - results of the extended follow-up of the first study population [abstract no. 314]. Proc Am Soc Clin Oncol 2000 May 20; 19: 82a
38. Jaschke A, Bastert G, Solomayer EF, et al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up [abstract no. 529]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans
39. Saarto T, Vehmanen L, Blomqvist C, et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients [abstract no. 527]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans
40. Paterson A. Breast cancer I: discussion of posters 527-531 [online]. Available from URL: http://www.asco.org/ac/ 1,1003,_12-002511-00_18-0026-00_19- 0011053,00.asp [Accessed 2004 Sep 24]
41. Atula S, Powles T, Paterson A, et al. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf 2003; 26 (9): 661-71
42. Taylor D. Is bisphosphonate therapy affordable? In press
43. Romanus D, Iscoe N, DeAngelis C, et al. Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients [Epub ahead of print]. Available from URL: http://springerlink. metapress.com [Accessed 2004 Oct 10]
44. Schering. About Bonefos(R): indications [online]. Available from URL: http://www.bonefos.com/scripts/professional/ 01_about_bonefos/01_01_indication. php [Accessed 2004 Oct 19]
45. Pavlakis N, Stockier M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2003; 3
46. Hortobagyi GN. Novel approaches to the management of bone metastases. Semin Oncol 2003; 30 (5 Suppl. 16): 161-6
47. Warr D, Johnston M, and members of the Breast Cancer Disease Site Group (Cancer Care Ontario). Use of bisphosphonates in women with breast cancer: practice guideline report #1-11 (Version 2.2002) [online]. Available from URL: http:// www.cancercare.on.ca/pdf/pebc1-11s.pdf [Accessed 2004 May 11]
48. BC Cancer Agency. Cancer management guidelines: breast: management: metastatic disease [online]. Available from URL: http://www.bccancer.bc.ca/HP1/ CancerManagementGuidelines/Breast/Management/MetastaticDisease.htm [Accessed 2004 May 10]
49. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003 Nov 1; 21 (21): 4042-57
50. Novartis Europharm Limited. Zometa (zoledronic acid): summary of product characteristics [online]. Available from URL: http://www.emea.eu.int/humandocs/ Humans/EPAR/zometa/ zometa.htm [Accessed 2004 Oct 19]
51. Novartis (US). Aredia(R) pamidronate disodium for injection: prescribing information [online]. Available from URL: http:// www.pharma.us.novartis.com/ product/pi/pdf/aredia.pdf [Accessed 2004 Oct 19]
52. Gralow JR. Bisphosphonates as adjuvant treatment for breast cancer. BMJ 2002 Nov 9; 325 (7372): 1051-2
53. Body JJ. Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis. Expert Opin Pharmacother 2003 Apr; 4 (4): 567-80
54. Roche UK. Summary of product characteristics: Bondronat (infusion) [online]. Available from URL: http://www.rocheuk.com/ProductDB/documents/rx/spc/ Bondronat_2mg_6mg_SPC.pdf [Accessed 2004 May 1]
55. Roche UK. Summary of product characteristics: Bondronat (tablets) [online]. Availabe from URL: http://www.rocheuk.com/ProductDB/documents/rx/spc/ Bondronat_50mg_FCT_SPC.pdf [Accessed 2004 May 1]
56. van Holten-Verzantvoort ATM, Hermans J, Beex LVAM, et al. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur J Cancer 1996, 32A (3): 450-4
57. Kokufu I, Kohno N, Takao S, et al. Adjuvant pamidronate (PMT) therapy for the prevention of bone metastasis in breast cancer (BC) patients (pts) with four or more positive nodes [abstract no. 530]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans
58. Brown JE, Coleman RE. The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Can Res 2002; 4 (1): 24-9
59. National Cancer Institute. Clinical trials [online]. Available from URL: http://www.cancer.gov/ClinicalTrials [Accessed 2004 May 12]
60. Coleman RE. Future directions in the treatment and prevention of bone metastases. Am J Clin Oncol 2002 Dec; 25 (6 Suppl 1.): S32-8
61. Plunkett TA, Rubens RD. Bisphosphonate therapy for patients with breast carcinoma: who to treat and when to stop. Cancer 2003; 97 (3 Suppl.): 854-8
62. Schmid P, Possinger K. Bisphosphonates in metastatic breast cancer. Breast Cancer Res & Treat. 2003; 81 Suppl 1.: S87-93
63. Neville-Webbe HL, Coleman RE. The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia. Palliat Med 2003; 17 (6): 539-53
64. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosponates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-34
65. Hohneker JA. (Novartis Oncology Medical Affairs and Services) Dear Doctor letter [online]. Available from URL: http:// www.fda.gov/medwatch/safety/2004/ ZometaHCP.pdf [Accessed 2004 Oct 26]
66. Body JJ. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 2001 Aug; 28 (4 Suppl. 11): 49-53
67. Liberato NL, Marchetti M, Barosi G. Clinical and economic issues in the treatment of advanced breast cancer with bisphosphonates. Drugs Aging 2003; 20 (9): 631-42